Call karma what you will. But she does not deserve to be called one of those multiple “B words” that Carly Fiorina has been dubbed, because last week, she put “Pharma Bro” Martin Shkreli in his place.
You may recall Shkreli as the former hedge fund manager and founder of Turing Pharmaceuticals who spiked the price of Daraprim — a drug that treats a rare infection for those battling HIV/AIDS — by more than 4,000 percent.
With his smarmy grin and dippity-do hair style, people quickly began to troll the guy on Twitter and hate his guts. Just when Shkreli thought he could no wrong, the right thing happened, according to Bloomberg. He was arrested for securities fraud.
Prosecutors in Brooklyn charged him with illegally taking stock from Retrophin Inc., a biotechnology firm he started in 2011, and using it to pay off debts from unrelated business dealings. He was later ousted from the company, where he’d been chief executive officer, and sued by its board.
The report notes that Retrophin sued Shkreli in August for misuse of company funds, claiming “he engineered numerous transactions between investors in his defunct hedge fund,” MSMB Capital Management and his biotechnology firm. In a complaint filed in Manhattan federal court, MSMB said that Shkreli cost them more than $7 million, leaving it virtually bankrupt.
In retort, Shkreli said:
“The $65 million Retrophin wants from me would not dent me. I feel great. I’m licking my chops over the suits I’m going to file against them”
Before he does that, he may have to sell a Wu-Tang Clan album that he reportedly paid $2 million to get, and then told Wu fans everywhere that he has no intention of streaming it. While that may be that bad, rumor was Taylor Swift wanted to listen to it (because she’s never met a story she didn’t like). To wit, Pharma Bro said:
“If Taylor Swift wants to come over and suck my d—, I’ll play it for her.”
Yep, karma’s a bitch.